Navigation Links
Oncotest GmbH and Debiopharm Group Announce a Successful Partnership in the Identification of Biomarker Candidates
Date:4/24/2013

LAUSANNE, Switzerland, April 24, 2013 /PRNewswire/ --

Oncotest GmbH and Debiopharm Group™ (Debiopharm) a Swiss-based global biopharmaceutical group, are pleased to announce the successful completion of the first biomarker projects at Oncotest. In a recent study, pharmacological data was generated with Debiopharm's investigational compound in Oncotest's 3D assay system for patient-derived xenografts and correlated with the extensive Oncotest's genomic and transcriptomic data. The collaboration resulted in the identification of several predictive biomarkers candidates including a gene signature.

"We are enthusiastic to work with Debiopharm on these projects and are looking forward to continue and expand our collaboration. I am convinced that the concept of deriving predictive biomarkers for new drugs already in a preclinical setting will make an impact. Ultimately, it has a significant potential to lower the attrition rates in clinical trials. Today, with our new biomarker department and the characterization data available for our tumor models, Oncotest is ideally positioned in this area." said Prof. Heiner Fiebig , Founder and CEO of Oncotest.

Dr. Hiroaki Tanaka , Personalized Medicine Director at Debiopharm added: "Reliable preclinical models are key success factors in drug development. We believe that technologies based on the direct use of patient tumors have a game-changer potential in translational research in oncology. We are happy to collaborate with Oncotest, a pioneer and a leader in the area, and we are looking forward to extending our partnership even further towards the achievement of personalized medicine."

About Oncotest

Oncotest is a CRO dedicated to the preclinical profiling of novel anti-cancer molecules, facilitating the optimal planning of clinical trials. Promising indications, novel combinations of anti-cancer molecules and potential biomarkers are identified using a combination of in vitro and in vivo tests with Oncotest's extensively characterized collection of more than 400 unique patient-derived tumor xenografts (PDX) propagated in nude mice. PDX are known to replicate patient tumor responses to anti-cancer drugs to a high degree. Ex vivo 3D assays are an important component of Oncotest's assay portfolio and standard panels of up to 200 PDX are offered for 3D assay campaigns. Clients benefit from Oncotest's industry leading experience.
Oncotest, based in Freiburg, Germany, was founded in 1993 by Prof. Heiner Fiebig , a clinical oncologist who pioneered the use of PDX for anti-cancer drug discovery and development. The company is focused on preclinical pharmacology of anti-cancer agents and works with large pharmaceutical and biotech companies. http://www.oncotest.de

About Debiopharm Group™

Debiopharm Group™ (Debiopharm) is a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs. The group in-licenses, develops and/or co-develops promising biological and small molecule drug candidates having reached clinical development phases I, II or III, as well as earlier stage candidates. It develops its products for global registration and maximum commercial potential. The products are out-licensed to pharmaceutical partners for sales and marketing. Debiopharm is also active in the field of companion diagnostics with a view to progressing in the area of personalized medicine. Debiopharm independently funds the worldwide development of all of its products while providing expertise in pre-clinical and clinical trials, manufacturing, drug delivery and formulation, and regulatory affairs.

For more information about Debiopharm Group™, please visit: http://www.debiopharm.com.

Debiopharm S.A. Contact
Beatrice Hirt
Communication Coordinator
bhirt@debiopharm.com
Tel.: +41-21-321-01-11

Additional Media Contacts
In London
Maitland
Brian Hudspith
Tel.: +44(0)20-7379-5151
bhudspith@maitland.co.uk

In New York
Russo Partners, LLC
Martina Schwarzkopf , Ph.D.
Account Executive
Tel.: +1-212-845-4292
Fax: +1-212-845-4260
martina.schwarzkopf@russopartnersllc.com

Oncotest GmbH Contact
Dr. Ingmar Peitz
Business Development
Ingmar.Peitz@Oncotest.de
Tel.: +49(0)761-51559-42



'/>"/>
SOURCE The Debiopharm Group
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Debiopharm Announces First Patient Enrolled in Phase III Study for the Rare Disease Central Precocious Puberty
2. MiMedx Group, Inc. Announces Listing on the NASDAQ Capital Market
3. The SDS/MSA Support Group Officially Changes Name to The Multiple System Atrophy Coalition
4. Many Ginkgo Extracts Safe, Says Herbal Science Group
5. Dr. Vasquez at the Connecticut Plastic Surgery Group Now Offers the Unique Crisalix 3D Simulations for Facial Aesthetics and Breast Augmentation
6. MiMedx Group, Inc. Announces Release Date for 2013 First Quarter Results
7. Dermatology Associates Medical Group in Beverly Hills Announces Safe, Fast Anti-Aging Laser Treatment
8. Atlantica Group LLC to Support International "Soft-Landing" Efforts of Incubators and Accelerators
9. Douglas Harrington, MD Addresses Select Group Of Physicians Regarding Latest Advances In Cardiovascular Risk Assessment
10. EAS Consulting Group, Experts in Quality Regulatory Services Related to FDA Issues, Announces Upcoming Dietary Supplement Seminars in Salt Lake City
11. Cellular Biomedicine Group Appoints Dr. Jianping Dai to the Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... 2017 /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ) ... to increase the size of the offering by 75% and ... with warrants to purchase 1,842,106 shares of common stock of ... of common stock (the "Exercise Price"), at a price to ... "Public Price"). The warrants have a term of four (4) ...
(Date:1/24/2017)... MA, USA & Geneva, Switerland (PRWEB) , ... ... ... pleased to announce the first commercially available malaria Plasmodium falciparum culture panels with ... P. falciparum culture panels, which are available in a range of concentrations from ...
(Date:1/24/2017)... Washington, DC (PRWEB) , ... January 23, 2017 ... ... nutrition and food security, is the first-ever recipient of the National Academy of ... contribution to global food security and nutrition. , The annual National Academy of ...
(Date:1/24/2017)... --  Instrument Business Outlook ( IBO ) ... ) the 2016 Company of the Year. ... developments in the analytical and life science instrumentation ... outstanding technical, operational and financial results throughout the ... "In 2016, Bio-Techne capitalized on opportunities in life ...
Breaking Biology Technology:
(Date:12/16/2016)... Dec. 16, 2016   IdentyTechSolutions America LLC ... products and solutions and a cutting-edge manufacturer of ... it is offering seamless, integrated solutions that comprise ... products. The solutions provide IdentyTech,s customers with combined ... facilities from crime and theft. "We ...
(Date:12/15/2016)... , Dec 15, 2016 ... Research and Markets has announced the addition ... offering. The report forecasts the global military biometrics market ... The report has been prepared based on an in-depth market ... and its growth prospects over the coming years. The report also includes ...
(Date:12/8/2016)... Market Research Future published a half cooked research report ... Security and Service Market is expected to grow over the CAGR ... Highlights: ... Mobile Biometric Security and Service Market is ... of authentication and security from unwanted cyber threats. The increasing use ...
Breaking Biology News(10 mins):